NCT01853800View on ClinicalTrials.gov

Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

July 31, 2013

Study Completion Date

August 31, 2013

Conditions
Biological Availability
Interventions
DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Trial Locations (1)

42096

Wuppertal

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

Bayer

INDUSTRY